BIOMAT Database Logo BIOMAT Database Logo

Effect of 50 mg enteric-coated aspirin (Astrix) on thromboxane and prostacyclin synthesis. 1987

M J James, and J A Walsh, and R K Foreman
Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia.

Although low-dose soluble aspirin can be recommended as a useful anti-thrombotic drug regimen in patients with vascular disease, enteric-coated preparations have a theoretical advantage for aspirin preparations which are to be ingested daily for many years. We have demonstrated that a 50 mg enteric-coated aspirin formulation (Astrix) which has an absorption rate much lower than soluble aspirin, is sufficient to inhibit platelet thromboxane synthesis while causing no major decrease in vascular prostacyclin synthesis.

UI MeSH Term Description Entries
D011464 Epoprostenol A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY). Prostacyclin,Prostaglandin I2,Epoprostanol,Epoprostenol Sodium,Epoprostenol Sodium Salt, (5Z,9alpha,11alpha,13E,15S)-Isomer,Flolan,Prostaglandin I(2),Veletri
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005343 Fibrinolytic Agents Fibrinolysin or agents that convert plasminogen to FIBRINOLYSIN. Antithrombic Drug,Antithrombotic Agent,Antithrombotic Agents,Fibrinolytic Agent,Fibrinolytic Drug,Thrombolytic Agent,Thrombolytic Agents,Thrombolytic Drug,Antithrombic Drugs,Fibrinolytic Drugs,Thrombolytic Drugs,Agent, Antithrombotic,Agent, Fibrinolytic,Agent, Thrombolytic,Agents, Antithrombotic,Drug, Antithrombic,Drug, Fibrinolytic,Drug, Thrombolytic,Drugs, Antithrombic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D013928 Thromboxane A2 An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS). Rabbit Aorta Contracting Substance,A2, Thromboxane

Related Publications

M J James, and J A Walsh, and R K Foreman
The effect of regular and enteric-coated aspirin on bleeding time, thromboxane, and prostacyclin.
July 1993, Prostaglandins, leukotrienes, and essential fatty acids,
M J James, and J A Walsh, and R K Foreman
Pharmacokinetics of enteric-coated aspirin and inhibition of platelet thromboxane A2 and vascular prostacyclin generation in humans.
August 1987, Clinical pharmacology and therapeutics,
M J James, and J A Walsh, and R K Foreman
Cumulative inhibitory effect of daily 40 mg aspirin on prostacyclin synthesis.
May 1981, Lancet (London, England),
M J James, and J A Walsh, and R K Foreman
Single-dose effect of enteric-coated aspirin on platelet function and thromboxane generation in middle-aged men.
April 1993, The Annals of pharmacotherapy,
M J James, and J A Walsh, and R K Foreman
Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric-coated aspirin 325 mg + immediate-release omeprazole 40 mg) or enteric-coated aspirin 325 mg + enteric-coated omeprazole 40 mg - a randomised, phase 1, crossover study.
July 2013, Alimentary pharmacology & therapeutics,
M J James, and J A Walsh, and R K Foreman
Comparison of enteric-coated aspirin and uncoated aspirin effect on bleeding time.
December 1998, Catheterization and cardiovascular diagnosis,
M J James, and J A Walsh, and R K Foreman
Enteric coated aspirin.
April 2007, The American journal of medicine,
M J James, and J A Walsh, and R K Foreman
Enteric-coated aspirin.
February 1983, Southern medical journal,
M J James, and J A Walsh, and R K Foreman
Letter: Effect of antacid on absorption of enteric-coated aspirin.
February 1974, JAMA,
M J James, and J A Walsh, and R K Foreman
Effect of cimetidine on bioavailability of enteric-coated aspirin tablets.
January 1983, Clinical pharmacy,
Copied contents to your clipboard!